Business Context and Reporting Period
Company: Establishment Labs Holdings Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 25, 2019
Reporting Period: Specific event date (June 25, 2019)
Context: The Company, an emerging growth company incorporated in the British Virgin Islands, reported the exercise of an option to purchase its manufacturing facility in Costa Rica.
Key Financial Metrics
This filing does not contain comprehensive financial statements, revenue, profit, cash flow, or margin data. The only specific financial metric disclosed is the transaction value for the asset acquisition.
- Asset Acquisition Cost: $3.45 million (Purchase price for manufacturing facility, land, and building).
- Debt and Liquidity: The filing text does not provide a clear value for current debt levels or liquidity positions.
Material Changes
The primary material change reported is the transition of the Company's manufacturing facility from a leased or optioned status to owned property.
- Transaction: On June 25, 2019, the Company's subsidiary, Establishment Labs, S.A., executed a deed to purchase the facility located at Building 25, Coyol Free Zone, Alajuela, Costa Rica.
- Asset Details: The facility comprises over 43,000 square feet of office and production space with a capacity to produce over 400,000 implants annually.
- Operational History: The facility opened in late 2016, with product shipments commencing in March 2017.
Outlook, Risks, and Unusual Items
Management Commentary: The filing highlights the facility's advanced infrastructure, including LEED Gold Certification (awarded August 2017) and energy-efficient systems (solar panels, energy-storage batteries, ice-bank cooling) that generate up to 80% of the building's total energy consumption.
Risks and Contingencies: No specific risks or contingencies were detailed in this report beyond the standard reference to the deed text for complete legal terms.
Unusual Items: None reported.
Investor Verification Checklist
- Verify the terms of the deed filed as Exhibit 10.1 for any covenants or conditions attached to the $3.45 million purchase.
- Confirm the impact of this capital expenditure on the Company's cash reserves and future debt obligations in subsequent quarterly reports (10-Q).
- Review the Company's production capacity utilization rates to ensure the 400,000 implant annual capacity aligns with current demand.
- Monitor the operational status of the energy micro-grid and solar systems to validate the claimed 80% energy generation efficiency.